|
September 20, 2007 For Immediate Release Drugs and Devices in the Clinical Management of Obesity Worldwide; New Report from MedMarket Diligence, LLC
FOOTHILL RANCH, CA --- Technologies for the management of obesity span surgical approaches, medically supervised diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence has maintained a focus on ongoing developments in the field obesity management and has completed a 2007 analysis on the worldwide market for products in the management of obesity.
"The recent decision by Sanofi-aventis to withdraw its FDA application for the anti-obesity drug rimonabant, marketed as Acomplia, highlights the need for an effective pharmaceutical treatment for obesity," says Patrick Driscoll, President of MedMarket Diligence. "It is clear that an effective pharmaceutical treatment will hold tremendous potential to compete with all obesity treatment types, but drug prospects have paled compared to current successes of bariatric surgical devices." The obesity treatment market worldwide is set to grow enormously, and will reach $6.4 billion by 2015. This includes prescription drugs for weight loss and maintenance; devices used in bariatric surgery and follow-up; and the predicted sales of drugs and devices with anticipated launch dates through 2015. The MedMarket Diligence report on the "Worldwide Market for the Clinical Management of Obesity" describes the clinical trends in the management of the obese, the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy. The report provides a current and forecast market for these products in the U.S., Europe and Rest of World, and profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management. The report is described, with preliminary table of contents, at http://www.mediligence.com/rpt/rpt-s825.htm. The report can be purchased directly online. For additional information, contact Patrick Driscoll, at (949) 859-3401, or patrick {at} mediligence {dot} com.
About MedMarket Diligence |
|
Patrick Driscoll founded MedMarket Diligence in October 2001. Mr. Driscoll has over 20 years experience analyzing and writing on medical technology markets, encompassing medical devices, biotech and biopharmaceuticals. He was co-founder of Medtech Insight and prior to that, a principal at Medical Data International, and in these organizations built syndicated reports businesses and directed the companies' custom consulting activities. Mr. Driscoll received a BS from the University of Dallas, and an MBA from the University of New Hampshire's Whittemore School of Business & Economics. Email: patrick[at]mediligence[dot]com.
Dona Watson is the Managing Editor of MedMarkets. Ms. Watson has an
extensive editorial background and focus serving the information needs of the
medical technology industry. She has served in editorial, analyst and
writer positions for the MedPro Month publication of Medical Data International,
as well as Nicholas Communications, and Biomedical Business International.
In addition, Ms. Watson was president of Catalyst Communications, where she was
publisher for an industry newsletter devoted to reimbursement of medical
products. Ms. Watson received a BA from Vanguard University. Email:
dona[at]mediligence[dot]com. Contact us:
© 2001- MedMarket Diligence, LLC. All rights reserved. |